Efficacy and safety of immunotherapy in elderly patients with non-small cell lung cancer

Non-Small Cell Lung Cancer (NSCLC) is the second most common malignancy worldwide and its incidence increases with age, with about half of the cases diagnosed in people aged ≥70 [1].

Source: Lung Cancer - September 9, 2019 Category: Cancer & Oncology Authors: Giulia Galli, Alessandro De Toma, Filippo Pagani, Giovanni Randon, Benedetta Trevisan, Arsela Prelaj, Roberto Ferrara, Claudia Proto, Diego Signorelli, Monica Ganzinelli, Nicoletta Zilembo, Filippo de Braud, Marina Chiara Garassino, Giuseppe Lo Russo Source Type: research